IRIS UniCatt

Baldin, Gianmaria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.195
AS - Asia 917
EU - Europa 641
SA - Sud America 234
AF - Africa 30
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.019
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.149
SG - Singapore 414
CN - Cina 238
BR - Brasile 191
SE - Svezia 145
FR - Francia 115
IT - Italia 115
DE - Germania 89
VN - Vietnam 77
IN - India 54
FI - Finlandia 33
GB - Regno Unito 30
ID - Indonesia 30
IE - Irlanda 30
JP - Giappone 27
CA - Canada 25
AR - Argentina 20
PL - Polonia 17
RU - Federazione Russa 14
HK - Hong Kong 13
MX - Messico 13
KR - Corea 11
AT - Austria 10
BD - Bangladesh 10
TR - Turchia 10
ZA - Sudafrica 10
ES - Italia 8
CO - Colombia 7
EC - Ecuador 7
KE - Kenya 7
UA - Ucraina 7
BE - Belgio 6
IQ - Iraq 4
LT - Lituania 4
NL - Olanda 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
CL - Cile 3
TN - Tunisia 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AZ - Azerbaigian 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
IR - Iran 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
PS - Palestinian Territory 2
SA - Arabia Saudita 2
TW - Taiwan 2
UZ - Uzbekistan 2
AO - Angola 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
JM - Giamaica 1
JO - Giordania 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TH - Thailandia 1
Totale 3.019
Salva come PNG Salva come JPEG
Città #
Singapore 230
Chandler 189
San Jose 124
Ashburn 122
New York 64
Beijing 37
Hefei 36
Dublin 30
Rome 29
Ho Chi Minh City 28
The Dalles 28
Lauterbourg 27
St Louis 26
Tokyo 26
Redmond 25
San Mateo 25
Los Angeles 24
Jakarta 23
Nanjing 22
Boston 21
Milan 21
São Paulo 21
Hanoi 19
Munich 18
Frankfurt am Main 17
Cattolica 16
Helsinki 16
Dearborn 15
Princeton 15
Redwood City 15
Wilmington 14
Marseille 11
Montreal 11
Paris 11
Brooklyn 10
Hong Kong 10
Jacksonville 10
Kent 10
Orem 10
Santa Clara 10
Seoul 10
Buffalo 9
Chicago 9
Turku 9
Guangzhou 8
Toronto 8
Warsaw 8
Bexley 7
Changsha 7
Mumbai 7
Vienna 7
Belo Horizonte 6
Brussels 6
Chennai 6
Denver 6
London 6
Moscow 6
Shenyang 6
Tianjin 6
Atlanta 5
Da Nang 5
Johannesburg 5
Mexico City 5
Washington 5
Buenos Aires 4
Düsseldorf 4
Houston 4
Jiaxing 4
Jinan 4
Kraków 4
Lappeenranta 4
Nairobi 4
Nanchang 4
Phoenix 4
Poplar 4
Querétaro 4
Shanghai 4
Stockholm 4
Alcalá de Henares 3
Augusta 3
Biên Hòa 3
Brasília 3
Campinas 3
Fairfield 3
Guarulhos 3
Haiphong 3
Lawrence 3
Mountain View 3
New Delhi 3
Nuremberg 3
Ottawa 3
Portland 3
Quito 3
Ribeirão Preto 3
Rio de Janeiro 3
Roubaix 3
Seattle 3
Abidjan 2
Amsterdam 2
Ankara 2
Totale 1.697
Salva come PNG Salva come JPEG
Nome #
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 154
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 137
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice 136
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure 136
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: A retrospective study from the clinical practice 135
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 134
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 133
An outbreak of acute hepatitis A among young adult men: clinical features and HIV coinfection rate from a large teaching hospital in Rome, Italy 126
Efficacy and safety of raltegravir in switch strategies in virologically suppressed patients: long-term data from clinical practice 126
Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication 118
HIV and vicarious stigma in a cohort of people living with HIV in Italy: What happens when the stigma is fueled by healthcare providers? 117
Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 117
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 116
Efficacy of Lamivudine Plus Dolutegravir vs Dolutegravir-Based 3-Drug Regimens in People With HIV Who Are Virologically Suppressed 107
Differences in the Long-term Impact of the COVID-19 Pandemic on the Mental Health and Professional Quality of Life of Resident and Specialist Physicians 106
Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study 106
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 105
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy 103
Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: A real life multicentre cohort 101
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 95
Predictors of choice of initial antifungal treatment in intraabdominal candidiasis 92
Real World Data from an Italian Outpatient Clinical Setting and from Home Care Assistance of Treatment-Experienced PWH Switching to CAB + RPV Regimen: A Prospective Observational Study 91
Necrotizing mpox with persistent microbiological positivity despite the use of tecovirimat: A case report 87
Autochthonous dengue outbreak in Rome, Italy, in 2023 84
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice 83
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV 79
Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice 79
Assessing dengue seroprevalence among people living with HIV (PLWH) in rome, Italy: Insights from the 2023 Italian autochthonous outbreak 69
Totale 3.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.506
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.506
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202136 0 0 0 0 0 0 0 0 0 13 17 6
2021/2022155 4 0 4 24 5 6 0 27 3 15 25 42
2022/2023438 63 65 38 61 24 46 25 40 54 1 11 10
2023/2024221 13 40 4 20 4 79 6 6 1 8 21 19
2024/2025562 13 8 46 28 46 28 45 19 46 41 137 105
2025/20261.334 191 52 93 216 252 65 225 58 83 99 0 0
Totale 3.072